Among inherited diseases of the liver, Crigler-Najjar type 1 disease (CN-1), which results from complete deficiency in bilirubin UDP-glucuronosyltransferase activity (B-UGT1), is an attractive target for gene therapy studies. Hyperbilirubinemic Gunn rats, a model of CN-1, were injected at 2 days of age with lentiviral or oncoretroviral vectors encoding the human B-UGT1. After injection, bilirubinemia was normalized for up to 95 weeks. Bilirubin conjugates were present in the bile, demonstrating liver transduction. PCR and enzyme activity analysis confirmed gene and phenotype correction in liver. We observed that when using a strong viral promoter, a complete correction was achieved with less than 5% of B-UGT1 copy per haploid genome and after a reconstitution of 12% B-UGT1 normal activity. Liver histology remained normal throughout the experiment and tissue distribution analysis revealed preferential hepatocyte transduction after systemic delivery. Finally, no adverse immune response occurred even after induction of nonspecific liver inflammation, suggesting immune ignorance to the therapeutic protein. Our present results document the lifelong safety of gene therapy for CN-1 with retroviral vectors. They offer a better delineation of liver gene correction level required to achieve complete correction of bilirubinemia and pave the way for future clinical application of gene therapy for inherited liver disorders.
Introduction
Crigler-Najjar type 1 disease (CN-1) is a genetic disorder characterized by high levels of unconjugated bilirubin due to complete absence of hepatic bilirubin UDPglucuronosyltransferase (B-UGT1; EC 2.4.1.17) activity. This rare recessive inherited disorder is an attractive candidate disease for gene therapy. Indeed, it is a serious, potentially life-threatening ailment, and the only curative alternative to phototherapy is liver transplantation. New curative options are therefore needed. Moreover, the histology of the liver parenchyma remains strictly normal throughout the course of the disease, thus maintaining easy access of blood-borne gene transfer vectors to hepatocytes across the hepatic fenestrated endothelium.
During the past decade, a wide array of gene transfer vectors have been tested for their capacity to correct hyperbilirubinemia in Gunn rats, a mutant jaundiced rat, which replicates the human disease. These studies have revealed that complete and permanent correction was not easily achieved by gene transfer strategies, and most attempts resulted in only partial or transient correction of hyperbilirubinemia. Such failures were consecutive to either immune elimination of virus-infected hepatocytes 1, 2 or to the weak capacity of some viral vectors to drive high expression of B-UGT1 or to transduce a sufficient proportion of hepatocytes. [3] [4] [5] Recently, Toietta et al. 6 reported the first complete cure of Gunn rat after delivery of a gutted adenoviral vector to adult animals. The correction was sustained for the life of the animals (2 years) without significant toxicity. Our laboratory also reported that delivery of murine leukemia virus (MLV)-based retroviral or lentiviral vectors to newborn Gunn rats could normalize bilirubinemia for at least 40 weeks. 7, 8 These seminal studies demonstrated the therapeutic validity of an in vivo approach for correcting CN-1, a model for gene therapy of metabolic diseases, and paved the way for future clinical application. However, designing a clinical trial will require better delineation of liver gene correction level required to achieve therapeutic reduction of serum bilirubin. Also, the potential immune response directed to the therapeutic protein has to be evaluated, in particular in a situation of inadvertent liver inflammation. Finally, toxicity and dissemination analysis of viral vector delivered to the blood stream or to the portal vasculature should be carried out to comply with regulatory requirements.
The aim of the present report is to bring new insights regarding the correlation between phenotype correction, restoration of enzyme activity and hepatocyte transduction level in successfully cured Gunn rats. This was achieved in cohorts of Gunn rats that received at birth recombinant lentiviral vectors or MLV-based retroviral vectors carrying the human B-UGT1 cDNA under transcriptional control of a ubiquitous or a liver-specific promoter. We also studied in cured animals whether induction of liver inflammation could unmask immune response against the therapeutic protein and be deleterious for phenotype correction.
Results

Long-term assessment of bilirubin metabolism
A first cohort of animals was injected at 2 days of age with MLV-based retroviral vectors carrying the human B-UGT1 cDNA under control of the viral long terminal repeat (LTR) (cohort RV-LTR, 10 8 infectious particles/ animal). A second cohort received lentiviral vectors carrying the same cDNA under control of a liver-specific promoter 9 (cohort LV-mTTR, 5 Â 10 8 infectious particles/ animal). A cohort of nontreated littermates was used as a control. We monitored serum bilirubin in treated Gunn rats for up to 95 weeks ( Figure 1 ). In the RV-LTR cohort, serum bilirubin was below normal level (that is 10 mM) in all animals at 6 weeks and remained at the same level until killing. In the LV-mTTR cohort, serum bilirubin was also normalized until killing. We obtained bile specimen from all experimental animals, and the relative proportion of bilirubin monoconjugate and diconjugate was assessed by high-performance liquid chromatography. As shown in Table 1 , bilirubin monoconjugates and diconjugates were present in all experimental animals. In the RV-LTR and LV-mTTR cohort animals, there was a predominance of bilirubin diconjugates as observed previously.
7,8
Hepatocyte transduction
To better document a correlation between phenotype correction and transduction level, we first determined by quantitative PCR the number of B-UGT1 cDNA copies present in the liver of treated animals at the time of killing (95 weeks post-injection). As shown in Table 1 , the number of copy per haploid genome in the RV-LTR cohort varied from 0.03 to 0.17 (0.07570.05). In the LVmTTR cohort, the PCR values were at least one order of magnitude higher with a mean of 2.07470.64 vector copy number per haploid genome. Next, to determine the transduction efficiency of hepatocytes and nonparenchymal cells after lentiviral vector administration, a cohort of animals was injected at 2 days of age with lentiviral vectors encoding green fluorescent protein (GFP) under control of the ubiquitous elongation factor 1-a promoter. Indeed, we and others could not detect human B-UGT1 enzyme in liver sections by immunohistochemistry using the WP1 anti-human B-UGT1 antibody. 10 As shown on Figure 2 , hepatocytes and nonparenchymal cells expressing GFP were detected on liver sections of rats injected with lentiviral vectors. However, the actual number of transduced nonparenchymal cells was low and always below 1% transduced cells.
B-UGT1 enzyme in transduced liver
We next evaluated the presence of B-UGT1 enzyme in the liver by western blotting. The human enzyme (55 kDa) was observed in all treated animals although at various levels and at a higher amount in LV-mTTR cohort ( Figure  3) . B-UGT1 enzyme activity was next measured in liver fragments obtained from treated animals ( Table 1 ). As shown in Figure 4 , the highest levels of B-UGT1 activity were observed in the LV-mTTR cohort (142.8744.6 U/l) and the mean level of B-UGT1 activity was about 10-fold higher than that observed in the RV-LTR cohort. In LV-mTTR animals, B-UGT1 level activity is beyond the normal value usually found in human liver (20-50 U/l) or in normal Wistar rats (30-35 U/l). Three animals in the RV-LTR cohort had B-UGT1 activity level equivalent to or closed to the normal value found in human liver. The others had B-UGT1 activity equivalent to 12-19% of the mean normal value found in human liver.
Tissue distribution and toxicology
Systemic delivery of viral vectors may result in broad organ distribution of the transgene. We monitored the presence of human B-UGT1 cDNA in various organs from three to five animals from each cohort by semiquantitative PCR. Typical results are presented in Figure 5 . In the RV-LTR cohort, the vast majority of the PCR signal was found in the liver although a faint band was also present in muscle, spleen and pancreas. In the LV-mTTR cohort, a positive signal was detected in all organs at various levels. This demonstrated that a larger panel of organs is transduced after lentiviral vector than MLV-based retroviral vector administration.
Lentiviral as well as MLV-based retroviral vectors are able to integrate into the infected cell's genome and potentially may induce insertional mutagenesis. We, therefore, carefully analyzed various tissues harvested from animals at killing (brain, kidney, lung, muscle and liver), but never detected gross anomalies in any of these organs. We focused our histological analysis on the liver, which is the preferential target organ. The liver histology remained normal for all animals (data not shown) and we never detected foci of transformed cells or preneoplastic lesions in the liver that were examined. In 
Absence of immune response to the transgene product
One critical issue for clinical development of gene therapy is the induction of an immune response against the transgene product. It has long been described that gene delivery to the newborn may avoid the generation of an immune response towards the therapeutic protein. However, any nonspecific inflammation process could trigger an immune response by inducing a deleterious danger signal to the liver. To address this issue, some of the experimental animals received an intravenous (i.v.) injection of concanavaline A (ConA), which is known to induce transient T-cell-dependent hepatitis. 11 Histological analysis of liver sections revealed the presence of numerous lymphocytic infiltrations in the liver, as well as apoptotic cells in ConA-injected animals (Figure 6a ), which was not observed in normal liver. Mild hepatitis was shown by an increase in serum ALAT at 7 and 24 h after injection (Figure 6b , Po0.05 using analysis of variance (ANOVA)). A dose of ConA 410 mg/kg was lethal for Gunn rats. We then monitored serum bilirubin level after ConA injection to detect any increase that could have indicated immune rejection of transduced cells. However, in all animals, serum bilirubin remained stable for at least 4 weeks after ConA injection ( Figure 6c ). In three animals, we were able to harvest a liver biopsy before ConA treatment. We then compared B-UGT1 activity in these animals before and after ConA 14 The design of gene transfer strategies adapted to large mammals represents one major challenge for in vivo gene therapy. Preliminary reports demonstrated that transduction level obtained in rodents is difficult to maintain in larger animals. 15 It is therefore critical to optimize each parameter of gene transfer to ensure a sufficient correction level in human patients. It is also worth noting that therapeutic threshold for a metabolic activity depends on the target disease and that vector transduction efficiency per se is not a reliable indicator for attaining this threshold. Our present report brings some insights into answer these questions for liver gene therapy of metabolic diseases using CN-1 as a prototypic enzyme deficiency.
First, we demonstrate that lentiviral and MLV-based retroviral vectors are therapeutic and equally proficient in jaundiced Gunn rats. Both vectors allowed a rapid and lifelong normalization of serum bilirubin. We did observe higher transduction efficiency with lentiviral vectors after neonatal in vivo gene delivery. This may be due to their capacity to transduce non-dividing cells in contrast to MLV-based retroviral vectors, which are restricted to actively dividing cells. The average copy number in liver in the RV-LTR cohort was 30-fold lower than the mean copy number in LV-mTTR cohort although the amount of viral particles administered was only fivefold lower for RV-LTR-injected animals (1 Â 10 8 vs 5 Â 10 8 infectious particles/animal). However, we cannot exclude that a nonlinear transduction efficiency/vector dose response at the vector dose used, as Figure 4 Relationship between B-UGT1 activity and vector copy in treated Gunn rats. B-UGT1 activity was evaluated in vitro on liver biopsies from RV-LTR (open square) and LV-mTTR (closed circle) cohort, and quantitative PCR was performed to determine the vector copy number per haploid genome, as described in Materials and methods. Rats in LV-mTTR cohort had higher transduction efficiency in the liver and B-UGT1 activity as compared to rats in RV-LTR cohort. Each plot corresponds to one experimental animal. B-UGT1 activity range found in human liver is indicated. Gene therapy of Crigler-Najjar disease TH Nguyen et al observed by van der Wegen et al. 16 (a twofold increase in vector dose resulted in 7.6-fold increase in transduction efficiency), and that a difference in titration procedures may also contribute to the difference in vector performance. Of note, we previously reported that up to 70% of hepatocytes were transduced after neonatal delivery of LV-mTTR lentiviral vectors, suggesting that hepatocytes were relatively well transduced as compared to nonparenchymal cells. 8 In fact, we observed that most of transduced cells were hepatocytes when neonates were injected with lentiviral vectors encoding GFP under the control of elongation factor 1-a promoter (Figure 2) . Such a result was also reported by others using neonatal injection of lentiviral vectors carrying another ubiquitous promoter. 17, 18 These results contrasted with those obtained when lentiviral vector was administrated in adults, where hepatocytes were hardly transduced and nonparenchymal cells accounted for most of transduced liver cells. 19, 20 This difference in hepatocyte transduction between neonates and adults suggested a different accessibility of the vector to hepatocytes, probably reflecting a better extravasation of vectors in regenerating (neonates) vs quiescent (adult) livers. In support to this assumption was that predominant transduction of hepatocytes was also reported in adult mice after stimulation of liver regeneration by two-thirds partial hepatotectomy or a primary mitogen. 21, 22 Interestingly, we observed a large panel of transduced extra-hepatic organs with lentiviral vectors, including heart, kidney and bone marrow. This may pave the way towards gene therapy of inborn cardiac, renal and hematopoietic disorders by neonatal gene delivery of lentiviral vectors. However, we detected a low amount of vector DNA in gonads. VandenDriessche et al. 17 also reported transduction in gonads and showed that transduced cells were not germ cells but endothelial cells, suggesting that lentiviral vectors were unable to extravasate from blood vessels into seminiferous tubules. More thorough studies should be performed in a larger number of animals to confirm absence of germline transmission, in particular absence of lentiviral vector DNA in the progeny of a mating between neonatally transduced animals and mock-transduced animals.
Second, we confirm that the promoter is a key parameter to achieve correct transgene expression at therapeutic levels after in vivo gene delivery, regardless of the vector type. The mean B-UGT1 activity level per vector copy, that is the relative vector promoter strength, was 2.5-fold higher in RV-LTR cohort than that found in LV-mTTR cohort (189.1796.3 vs 76.2732). As few nonparenchymal cells were transduced and hepatocytes represent about 70% of liver cells, the relative promoter strength of LV-mTTR vector was a close estimation of mTTR activity in hepatocytes. The strong expression of B-UGT1 from murine LTR allowed for curing Gunn rats despite much lower transduction efficiency in the RV-LTR cohort as compared to the LV-mTTR cohort. Of note, the relative activity per B-UGT1 copy of murine LTR and mTTR is about 11-and 4-fold beyond the mean normal value found in human liver, respectively. These results have direct consequences for the design of future gene therapy protocols. As an example, previous studies of cell transplantation have revealed that cell therapy of CN-1 by injection of normal hepatocytes representing up to 5% of the liver mass only resulted in an initial 50% decrease of serum bilirubin. 23 In this case of allogeneic transplantation, B-UGT1 expression was under control of the natural promoter. In our present study, serum bilirubin was normalized when liver B-UGT1 activity reached 4.2 U/l, corresponding to 12% of the mean value found in human liver. This supports the assumption that reconstitution of B-UGT1 activity in human liver to at least 10% of normal value would be therapeutic for CN-1. 23 We observed that when using a strong viral promoter, a complete correction was achieved with less than 5% of B-UGT1 copy per haploid genome. In a previous study, van der Wegen et al. 16 reported a gene correction level of 1.5 copy vector/haploid genome in the liver (and up to 34% transduction efficiency) after injection of lentiviral vectors carrying albumin enhancer/promoter in Gunn rats. However, treated rats had not normalized serum bilirubin (o10 mM). Evaluation of B-UGT1 activity per vector copy would be useful to determine the therapeutic threshold for gene correction to attain for the vector used by van der Wegen et al.
Altogether, our data provide a basis for delineation of the vector to be used in humans. For liver enzyme deficiencies, the enzymatic activity per vector copy number is the key parameter rather than transduction efficiency per se. It indicates the feasibility of a gene therapy protocol by providing the therapeutic threshold for gene correction level to attain. For the RV-LTR and LV-mTTR vectors used in this study, this threshold level appears attainable for treating CN-1 in humans. It is worth noting that lentiviral vectors would be preferably chosen for transduction of slowly dividing and quiescent liver, and MLV-based retroviral vector would be restrained to in utero or neonatal (shortly after birth) gene delivery. In addition, a liver-specific promoter, such as mTTR, 9 would be preferred to a ubiquitous promoter for targeting expression in hepatocytes and to protect transduced hepatocytes from their immune clearance.
Absence of an immune response to a non-self therapeutic protein has already been described after in vivo gene delivery to newborn animals. 24 Therefore, the absence of a humoral immune response against human B-UGT1 in our study is not surprising. However, it is also known that inflammation may precipitate immune response even in animals that were apparently tolerant to a foreign protein. 25 This is likely to occur in liver, where T-regulatory cells are sensitive to microbial signals 26 and in which hepatocytes are freely accessible to cytotoxic T-lymphocytes. 27 B-UGT1 is immunogenic 1, 28 and auto-antibodies directed against B-UGT1 were reported in patients with inflammatory liver diseases. 29 Since liver inflammation may occur during the life of any patient, it was therefore important to document if such situation could trigger elimination of corrected cells in our model. Our present results clearly indicate that therapeutic correction level remained stable despite induction of non-specific T-cell-dependent hepatitis. This supports the hypothesis that immune ignorance of hepatocytes expressing human B-UGT1 is strong. Finally, we showed that lifelong overexpression of B-UGT1 in hepatocytes by up to six fold (LV-mTTR cohort) is not deleterious for the transduced livers. Moreover, the absence of any tumoral process or abnormal liver histology in our animals after prolonged period of time, support the view that integrative gene transfer vectors, be it by MLV-based retroviral of lentiviral vector, This may protect them from any deleterious effect of recombinant genome integration that has already been described in highly proliferative hematopoietic stem cells. 30 Indeed, single integration is probably not sufficient alone to induce carcinogenesis and second hits are needed to trigger uncontrolled proliferation of cells. Our data are in agreement with previous studies based on lentiviral transduction and subsequent implantation of liver progenitor cells in the retrorsine/partial hepatectomy model. 31 The authors did not observe subsequent liver tumor formation although transduced cells actively divided.
Altogether, our data support the view that gene therapy for Crigler-Najjar disease based on in vivo administration of retroviral vectors to newborns or young patients deserves further studies in large animals before clinical application.
Materials and methods
Animals
Animals were housed at the animal facilities of Nantes University Medical School and received human care according to the guidelines of the french Ministère de l'Agriculture. Homozygous Gunn j/j 32 rats of both sex were used in this study. All viral vectors were injected in newborn homozygous Gunn rat via the temporal vein as described previously. 7, 8 ConA (Sigma, Lyon, France) was dissolved in phosphate-buffered saline (PBS) and injected i.v. in animals at a dose of 10 mg/kg.
Description and production of retroviral vectors
The self-inactivating mTTR-B-UGT1 lentiviral vectors encoded the human B-UGT1 under control of the liverspecific mTTR promoter, the murine transthyretin promoter fused to a synthetic hepatocyte-specific enhancer. 8 It also contained the cis-acting HIV-1 cPPT/ CTS 33, 34 upstream of mTTR promoter and the posttranscriptional regulatory element from the woodchuck hepatitis virus (WPRE) downstream of the transgene. 35 Recombinant lentiviruses containing WPRE sequence and GFP gene under control of the promoter from human elongation factor 1-a promoter 36 were also produced. High-titer lentiviral vector stocks were generated as described previously by transient transfection of three plasmids, the vector plasmid, the packaging plasmid pCMV R8.91 and the VSVG envelope proteincoding plasmid pMD.G, 37 and subsequent concentration of viral supernatants by tangential flow filtration (Spectrum laboratories) and ultracentrifugation (50 000 g, 90 min, 41C). Vector titers were determined on HeLa cells by real-time quantitative PCR. For this titration, primers and probe (Eurogentec) specific for 5 0 -untranslated lentiviral vectors were used: GAG-F, GGAGCTAGAACGATTCGCAGTTA; GAG-R, GGTTG TAGCTGTCCCAGTATTTGTC; GAG-P, 5
0 . For normalization of the amount of genomic DNA, primers and probe specific for b-actin gene were used: HB2-F, TCCGTGTGGATCGGCGGCTC CA; HB2-R, CTGCTTGCTGATCCACATCTG; 5 0 -(Yakima Yellow)-CCTGGCCTCGCTGTCCACCTTCCA-(Eclipse Dark Quencher)-3 0 . A standard curve was generated using DNA extracted from Hela-4.5 cells containing one copy of an HIV vector. Reactions were performed and analyzed using an ABI Prism 7700 sequence detection system (RE Applied Biosystems). The titer routinely reached 1 Â 10 10 transducing units/ml. The MLV-based retroviral vectors encoded the human B-UGT1 under the control of the retroviral LTR (MFG vector backbone). 7 A stable vector producer cell line was generated from 293GPG cells 38 and high-titer retroviral vector stock were produced by tangential flow filtration and ultracentrifugation. Titers were determined on Te671 target cells followed by quantitative PCR evaluation of the proportion of transduced cells. Real-time quantitative PCR (Eurogentec) was performed using Sybr Green dye and primers specific for human B-UGT1 (5 0 -GTGATG ATGCCCTTGTTTGGT-3 0 and 5 0 -AAACTCCACCCAGA ACAC-3 0 ) (Eurogentec). A standard curve was generated by transducing Te671 cells with MLV-retroviral vectors coexpressing human B-UGT1 and neo gene, 1 the viral titer of which had been determined previously according to G418 resistance. Viral titers were routinely 5 Â 10 8 transducing units/ml.
Liver function assays
Blood samples were drawn from retro-orbital sinus. Serum total bilirubin levels and ALAT, ASAT, g-GT and alkaline phosphatase activity were measured at the routine biochemistry department of Nantes University Hospital. ALAT activity was measured using the ALAT/ GPT kit according to the manufacturer's instruction (Roche, Meylan, France) on Hitachi 717 analyzer. Bile was harvested by laparotomy followed by bile duct canulation. The presence of monoglucuronide and diglucuronide bilirubin conjugates was assessed using alkaline methanolysis as described previously. 39 The relative amounts of the three types of bilirubin were determined by the integration of the areas under the chromatography peaks. Enzymatic activity of B-UGT1 was assayed on liver homogenates by the diazotation method of Black et al. 40 
Protein analysis
To prepare microsomes, livers were homogenized in a glass Dounce-type homogenizer in cold homogenization buffer containing 0.25 M sucrose, 10 mM Tris-HCl pH 7.4, 1 mM ethylenediaminetetraacetic acid (EDTA) and antiprotease mixture (complete EDTA-free protease inhibitors, Roche). The tissue homogenate was centrifuged at 10 000 g for 10 min at 41C, and the supernatant was centrifuged again at 105 000 g for 60 min at 41C to sediment microsomes. After centrifugation, the pellet was resuspended in cold homogenization buffer.
For western blot analysis, total liver microsome proteins (40 mg/lane) were resolved by electrophoresis and blotted onto nitrocellulose membranes. Human B-UGT1 was revealed by using rabbit polyclonal antibody WB-UGTA1 (1:1000, Gentest, Invitrogen, France), followed by incubation with an HRP-conjugated goat anti-rabbit IgG (1:1000, Gentest) and by detection with the enhanced chemiluminescence kit (Amersham Pharmacia, Saclay, Orsay, France).
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PCR analysis
PCR analysis was performed on high-molecular-weight DNA (500 ng) using two B-UGT1 primers (5 0 -TCTGCT ATGCTTTTGTCTGG-3 0 and 5 0 -GGATAGTGGATTTTGG TGAA-3 0 ) (Eurogentec) generating a 504-bp fragment. Semiquantitative PCR amplification (Promega, Charbonnieres, France) was performed by denaturation for 5 min at 941C, followed by 28 cycles of amplification (941C for 20 s; 601C for 30 s; 721C for 40 s) and a final extension for 10 min at 721C. The values were normalized for the amount of DNA using amplification of a 202-bp fragment of rat PEPCK gene (5 0 -GTCATATTTCTTCA GCTTGCG-3 0 and 5 0 -ATAATGGTCTGGACTTCTCTG-3 0 ) (Eurogentec) as an internal standard. Reaction conditions were 501C for 2 min, 951C for 10 min followed by 40 cycles at 951C for 15 s and 601C for 1 min. A standard scale was constructed using human genomic DNA diluted in various proportions with rat genomic DNA.
Histology and immunohistochemistry
The presence of GFP-positive cells was assessed by immunohistochemistry on formalin-fixed/paraffinembedded sections (5 mm), as described previously. 8 Sections were deparaffinized and endogenous peroxidase activity was inhibited by incubation for 30 min in a 3% H 2 O 2 solution in PBS. Monoclonal primary mouse anti-GFP antibody diluted 1:100 in PBS containing bovine serum albumin (2% w/v) and Tween 20 (0.1% v/v) was applied for 2 h at room temperature. Positive cells were revealed with biotinylated goat anti-mouse immunoglobulin and streptavidin-peroxidase using diaminobenzidine as a chromogenic substrate. After counterstaining with hematoxylin, the percentage of GFP-positive cells was calculated in at least 10 fields at Â 40 magnification.
Statistical analysis
Statistical analysis was performed using the Student's t-test. A P-value of less than 0.05 was considered to be statistically significant. Comparison between multiple groups was performed using ANOVA.
